Research Institute

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

  • IMMU-132 for Metastatic Urothelial Cancer

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)


Breast

Colon

Gastrointestinal

Genitourinary

Leukemia

Lung

Lymphoma

Melanoma

Ovarian

Pancreatic

Prostate

Renal

Solid Tumors